Fda approves cardiamp® heart failure ii protocol amendment to use proprietary cell population analysis screening to define treatment

Biocardia announced today that the fda has approved an important protocol amendment for the cardiamp heart failure ii trial, its confirmatory phase 3 trial

BCDA Ratings Summary

BCDA Quant Ranking